157 related articles for article (PubMed ID: 12633578)
1. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia.
Rubnitz JE; Pui CH
Cancer Treat Rev; 2003 Feb; 29(1):31-44. PubMed ID: 12633578
[TBL] [Abstract][Full Text] [Related]
2. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
3. Childhood acute lymphoblastic leukemia.
Pui CH; Relling MV; Campana D; Evans WE
Rev Clin Exp Hematol; 2002 Jun; 6(2):161-80; discussion 200-2. PubMed ID: 12196214
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary function after treatment for acute lymphoblastic leukaemia in childhood.
Nysom K; Holm K; Olsen JH; Hertz H; Hesse B
Br J Cancer; 1998 Jul; 78(1):21-7. PubMed ID: 9662245
[TBL] [Abstract][Full Text] [Related]
5. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
[TBL] [Abstract][Full Text] [Related]
6. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
7. Childhood acute lymphoblastic leukemia: update on prognostic factors.
Vrooman LM; Silverman LB
Curr Opin Pediatr; 2009 Feb; 21(1):1-8. PubMed ID: 19242236
[TBL] [Abstract][Full Text] [Related]
8. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.
Foroni L; Harrison CJ; Hoffbrand AV; Potter MN
Br J Haematol; 1999 Apr; 105(1):7-24. PubMed ID: 10366253
[No Abstract] [Full Text] [Related]
9. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.
Pui CH; Relling MV; Sandlund JT; Downing JR; Campana D; Evans WE
Ann Hematol; 2004; 83 Suppl 1():S124-6. PubMed ID: 15124703
[TBL] [Abstract][Full Text] [Related]
12. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
14. Acute lymphoblastic leukaemia.
Pui CH; Robison LL; Look AT
Lancet; 2008 Mar; 371(9617):1030-43. PubMed ID: 18358930
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
Yamaji K; Okamoto T; Yokota S; Watanabe A; Horikoshi Y; Asami K; Kikuta A; Hyakuna N; Saikawa Y; Ueyama J; Watanabe T; Okada M; Taga T; Kanegane H; Kogawa K; Chin M; Iwai A; Matsushita T; Shimomura Y; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2010 Dec; 55(7):1287-95. PubMed ID: 20535816
[TBL] [Abstract][Full Text] [Related]
16. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.
Bartram J; Wade R; Vora A; Hancock J; Mitchell C; Kinsey S; Steward C; Moppett J; Goulden N
Arch Dis Child; 2016 May; 101(5):449-54. PubMed ID: 26865705
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Koehler R; Bartram CR
Klin Padiatr; 2013 May; 225 Suppl 1():S40-4. PubMed ID: 23700054
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in childhood acute lymphoblastic leukemia.
Pui CH
J Formos Med Assoc; 2004 Feb; 103(2):85-95. PubMed ID: 15083238
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.
Balduzzi A; Valsecchi MG; Uderzo C; De Lorenzo P; Klingebiel T; Peters C; Stary J; Felice MS; Magyarosy E; Conter V; Reiter A; Messina C; Gadner H; Schrappe M
Lancet; 2005 Aug 20-26; 366(9486):635-42. PubMed ID: 16112299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
